You are here: Home » News-CM » Companies » News
Business Standard

Dr Reddy's Laboratories receives EIR for its API manufacturing plant at Miryalaguda

Capital Market 

From USFDA

Dr Reddy's Laboratories has received an Establishment Inspection Report from the USFDA following closure of audit of its API manufacturing plant at Miryalaguda. The Company was issued a form 483 with three observations subsequent to the audit of the said unit in February 2017.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU